Suchergebnisse - "Kato, Terufumi"

PubPharm (243)

81

Radiographic features and poor prognostic factors of interstitial lung disease with nivolumab for non-small cell lung cancer

enthalten in: Cancer science | 2021

von Saito, Y. | Sasaki, S. | Oikado, K. | +16

82

Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma : 3-Year Results of the MERIT Study

enthalten in: JTO clinical and research reports | 2021

von Fujimoto, N. | Okada, M. | Kijima, T. | +8

83

Suitability of Bronchoscopic Biopsy Tissue Samples for Next-Generation Sequencing

enthalten in: Preprints.org | 2021

von Murakami, S. | Yokose, T. | Nemoto, D. | +6

84

Suitability of Bronchoscopic Biopsy Tissue Samples for Next-Generation Sequencing

enthalten in: Diagnostics (Basel, Switzerland) | 2021

von Murakami, S. | Yokose, T. | Nemoto, D. | +6

85

Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L)

enthalten in: Molecular oncology | 2021

von Sakai, K. | Takahama, T. | Shimokawa, M. | +13

86

A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group 11719L/ADJUST study)

enthalten in: Therapeutic advances in medical oncology | 2021

von Shibaki, R. | Akamatsu, H. | Kato, T. | +7

87

Tissue surface area and tumor cell count affect the success rate of the Oncomine Dx Target Test in the analysis of biopsy tissue samples

enthalten in: Thoracic cancer | 2021

von Nemoto, D. | Yokose, T. | Katayama, K. | +11

88

Randomized phase II trial of S-1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer

enthalten in: Cancer medicine | 2021

von Shimokawa, T. | Yamada, K. | Tanaka, H. | +13

89

Overview of checkpoint inhibitor pneumonitis: incidence and associated risk factors

enthalten in: Expert opinion on drug safety | 2021

von Shibata, Y. | Murakami, S. | Kato, T.

90

Randomized phase II trial of S‐1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non‐small cell lung cancer

enthalten in: Cancer Medicine | 2021

von Shimokawa, T. | Yamada, K. | Tanaka, H. | +13